

Jin-Xiong She, President and CEO
Jinfiniti was founded by Dr. Jin-Xiong She, currently a Professor and Eminent Scholar in Genomic Medicine at the Georgia Health Sciences University (GHSU). He also serves as the director of GHSU's Center for Biotechnology and Genomic Medicine (CBGM), and vice chair of the GHSU Department of Pathology. Dr. She has almost three decades of research experience in multiple disciplines including genetics, genomics, proteomics, biomarker development, drug development and clinical research. Dr. She is a pioneer in many studies using high throughput technologies. Dr. She has published over 150 research papers and received several US patents. He has made significant discoveries throughout his scientific career. He has received over $70 million of research funding from the US government, Chinese Government and private foundations.
Dr. She has an extensive and successful track record in providing services for research and patient care. He served as assistant director for the Tissue Matching Laboratory at the University of Florida, a CLIA-certified clinical laboratory for the transplantation program. Dr. She also served for five years as the director of the Sequencing Core Facility of the University of Florida. He secured funding and directed the NIDDK Biotechnology Center at the University of Florida, which provided genomic services to over 10 research universities in the Southern US. Since 2002, Dr. She has been serving as director of the Genomics Core Facility and the Proteomics Core Facility at GHSU. More recently, Dr. She has established and directed CBGM's high throughput screening (HTS) facility for drug development.
Dr. She also has extensive experience in managing large and complex operations. From 2000 to 2002, he served as co-chief of the division of experimental pathology at the University of Florida, managing a research program with an annual budget of $3 million. Since 2002, Dr. She has established, grown and managed a high profile research program at GHSU with over 70 staff members and an annual research budget of over $10 million. Dr. She has extensive experience in managing multi-center basic and clinical research studies including the prospective assessment in newborns for diabetes autoimmunity (PANDA) and the environmental determinants of diabetes in the young (TEDDY), both being national or international consortia involving many study sites. Dr. She has also hold multiple national positions in research organizations and served on scientific advisory boards of biotechnology companies. Dr. She co-founded Jinfinity LLC, a successful real estate, and served as its vice president.

Richard A. McIndoe, Ph.D., Vice President for Operations and Information Technology
Dr. McIndoe has extensive industrial and academic experience in building laboratory information management systems (LIMS). He is the Associate Director of the Center for Biotechnology and Genomic Medicine (CBGM) and Professor of Pathology at GHSU. Dr. McIndoe has extensive experience in coordinating large-scale informatics initiatives and working within the auspices of multicenter consortia. He is the Director of the Coordinating and Bioinformatics Unit of the NIDDK/NHLBI Animal Models of Diabetic Complications Consortium and Mouse Metabolic Phenotyping Centers, Director of Bioinformatics for the PANDA project, the NIDDK Biotechnology Center, the GHSU TEDDY Center. The web-based systems designed by Dr. McIndoe store and integrate demographic data, clinical data, and environmental questionnaires as well as provide full scheduling and study management functions. Dr. McIndoe has been developing biomedical databases for over 15 years. Some of which have been commercialized. He has both academic and industrial experience developing databases for workflow systems (MADGE, Curagen Corp., MolecularStaging Inc.), clinical databases (PANDA, TEDDY), genomics (MADGE, SAGA, Curagen Corp.) and integrated data resources (AMDCC, MMPC). All of these systems provide highly scalable, robust database solutions to store and efficiently retrieve diverse data types. Dr. McIndoe is unique in that he has both a biological background as well as extensive experience in both software and database development.

Shelley Wu, MBA, Director of Sales
Ms. Wu is responsible for domestic and international sales for Jinfiniti Biosciences and has extensive background in business administration and biological sciences. She has over eight years of business management experience including sales, purchasing, shipping and operation. From 2007 to 2010, she joined Teco Diagnostics, where she had a successful career in biotechnology and international business. In addition, she had six years research experience in biomedical science. Shelley earned an MBA degree from the Anderson Graduate School of Management at the University of California, Riverside, a B.S. degree in Biology from Tunghai University, Taiwan and M.S. degree in Physiology from Yang-Ming University, Taiwan.